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Abstract 
 
Objectives: To evaluate construct validity, interpretability, reliability and responsiveness as well 
as determination of cut-off points for good and poor health within the original English version and 
the 18 translations of the disease-specific ASAS Health Index (HI) in 23 countries worldwide in 
patients with Spondyloarthritis (SpA). 
Methods: A representative sample of SpA patients fullfilling the ASAS classification criteria for 
axial (axSpA) or peripheral SpA (pSpA) was used. The construct validity of the ASAS HI was 
tested using Spearman correlation with several standard health outcomes for axSpA. Test-retest 
reliability was assessed by intraclass correlation coefficients (ICC) in patients with stable disease 
(interval 4-7 days). In patients who required an escalation of therapy because of high disease 
activity responsiveness was tested after 2-24 weeks using standardized response mean (SRM). 
Results: Among the 1548 patients 64.9% were male, with a mean (SD) age 42.0 (13.4) years. 
Construct validity ranged from low (age: 0.10) to high (BASFI: 0.71). Internal consistency was high 
(Cronbachs-α of 0.93). The reliability among 578 patients was good (ICC=0.87 (95%CI 0.84-
0.89)). Responsiveness among 246 patients was moderate-large (SRM= -0.44 for NSAIDs, -0.69 
for csDMARD, and -0.85 for TNFi). The smallest detectable change was 3.0. Values ≤5.0 have 
balanced specificity to distinguish good health opposed to moderate health and values ≥12.0 are 
specific to represent poor health opposed to moderate health. 
Conclusions: The ASAS HI proved to be valid, reliable, and responsive. It can be used to evalu-
ate the impact of SpA and its treatment on functioning and health. Furthermore, comparison of 
disease impact between populations is possible. 
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Introduction: 
Spondyloarthritis (SpA) is characterized by inflammation and new bone formation in the axial 
skeleton and joints.[1] Patients with SpA suffer from axial and peripheral symptoms resulting in 
pain, spinal stiffness, sleep problems, and fatigue.[2-4] Peripheral manifestations (arthritis, dac-
tylitis or enthesitis) and extra-articular manifestations such as uveitis, psoriasis and inflammatory 
bowel disease (IBD) may add to the burden of disease in a substantial number of patients but are 
less well studied.[5, 6] The course of disease varies but many patients experience functional dis-
ability and limitation in activities and social participation. The influence of the disease on health-
related quality of life and functional status has been well characterized in patients with ankylosing 
spondylitis (AS), and to a lesser extent for patients with non-radiographic axial SpA (nr-axSpA) 
but there is little data relating to patients with peripheral SpA (pSpA).[4, 6] 
The ASAS Health Index (ASAS HI) has been developed to measure functioning and health in 
patients with SpA with the aim of defining and comparing the impact of the disease and health in 
this patient group.[7] Initial phases in the development of the ASAS HI focused on investigating 
functional impairments from the patients perspective using both qualitative and quantitative ap-
proaches.  
The bio-psychosocial model of disease proposed by the International classification of functioning, 
disability and health (ICF) was used as the basis for the development of the ASAS HI. The ICF is 
accompanied by a classification of categories, called factors, that allow description of functioning, 
disability and health in individuals in a systematic and inclusive way.[8] The comprehensive ICF 
Core Set for AS is a disease specific selection of the ICF factors that are typical and relevant for 
AS, and has served as the underlying construct of the ASAS HI since the whole range of function-
ing, disability and health of patients with AS was captured. [9] Patients, rheumatologists and meth-
odologists were involved in the further reduction of categories using qualitative and quantitative 
methods and resulting finally in the ASAS HI. [7] The 17 dichotomous items of the ASAS HI ad-
dress aspects of pain, emotional functions, sleep, sexual functions, mobility, self-care and com-
munity life representing a wide spectrum of different levels of functioning, disability and health in 
patients with SpA. The sum score of the ASAS HI ranges from 0 to 17, with a lower score indicating 
a better health status. Preliminary validity and feasibility (time of completion) have already been 
assessed in a field test during the final steps of the development phase.[7] Cognitive debriefing 
was undertaken in patients with AS and nr-axSpA and patients with peripheral manifestations 
aiming at assessment of a broad impact of health on all patients with SpA. [7, 10] The ASAS HI 
was originally developed in parallel in English speaking countries (Australia, Canada, Ireland, UK, 
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USA), and it has later been translated and cross-culturally adapted into 18 languages worldwide. 
[10] 
The objective of the current paper is to evaluate construct validity, interpretability, reliability and 
responsiveness as well as determination of cut-off points for good and poor health within the orig-
inal English version and the 18 translations of the disease-specific ASAS HI in 23 countries world-
wide. 
 
Methods:  
Study design: A cross-sectional international observational study with a longitudinal component 
for reliability and responsiveness of the ASAS HI was performed in 23 countries during 2014 and 
2015. 
Patients:. A representative sample of SpA patients fulfilling the ASAS classification criteria for 
either axial (axSpA) or pSpA was recruited. [11, 12] Each centre was asked to recruit a sample of 
patients 80% of whom were to have axSpA and 20% pSpA with no more than 10% of all recruits 
having co-existent psoriasis. Of the axSpA subset 40% were to have nr-axSpA and 60% AS. There 
was a target of 50-100 recruits per country to reach an overall sample size of 1700 patients. The 
aim was to include patients with a broad range of disease severity and a variety of treatments. 
Patients with severe concomitant diseases which may influence their functional status were ex-
cluded from participation together with patients who were unable to understand the objectives of 
the study or the various questionnaires. Centres were asked to include at least 25% of their sample 
in the reliability arm and 25% in the responsiveness arm. All centres received approval from their 
local ethics committee. Written informed consent was obtained from all respondents prior to the 
start of their participation. 
Data collection: Demographic and clinical information was collected including age, gender, pre-
dominant presentation, presence of extra-articular manifestations, years of education and employ-
ment. C-reactive protein (CRP) levels, imaging results and current medications were also rec-
orded. Physicians judgment of patients’ overall functioning and health was assessed by a single 
global question (‘Please score the overall status of the subject`s signs and symptoms and the 
functional capacity of the subject”) on a zero to 10 numerical rating scale (NRS) (10 representing 
severe impairment) and a Likert scale (“How do you rate the health of your patient today?” on a 
4-point scale ranging from very poor to very good. Physician’s opinion on the level of disease 
activity was recorded by answering the question “How active was the spondyloarthritis of your 
patient during the last week?“. 
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Patients completed a series of self-reported questionnaires: ASAS HI [7], Bath Ankylosing Spon-
dylitis Disease Index (BASDAI) [13], Bath Ankylosing Spondylitis Functioning Index (BASFI) [14], 
EuroQol five dimensions questionnaire (EQ-5D-5L index and thermometer) [15], Short Form Sur-
vey Instrument 36-Item (SF-36) [16], Hospital Anxiety and Depression Scale (HAD-S) [17], work 
productivity and activity impairment questionnaire (WPAI) [18], and pain and spinal pain NRS (0–
10 NRS; 10 representing severe pain). Patient’s opinion on the level of disease activity was rec-
orded by a single patient global question (“How active was your rheumatic disease on average 
during the last week?”) on a NRS 0-10 and on the health status (“How do you rate your health 
today?”) on a 4-point Likert scale ranging from very poor to very good. Based on collected data, 
the ASDAS sum score was calculated and patients were categorized into ASDAS status 
groups.[19, 20] EQ-5D index was calculated using the value set for UK except for France, Ger-
many, Netherlands, Spain, Thailand and USA for which country specific value sets were used. 
ASAS HI: The ASAS HI contains 17 items (dichotomous response option: “I agree” and “I do not 
agree”) addressing different aspects of functioning. A sum score is being calculated by summing 
up all responses to “I agree” given a total ASAS HI score ranging from 0 to 17—with a lower score 
indicating a better and a higher score indicating an inferior health status (see also users manual 
for handling missing items (supplement 1). [7] 
Variables were collected at baseline and longitudinally in stable patients (reliability arm) or in pa-
tients who required a therapeutic change because of high disease activity (responsiveness arm) 
(flow chart and patients disposition in supplement 2). Longitudinal assessments were performed 
in patients who were in a stable disease state (reliability arm) or in patients who required a thera-
peutic change because of high disease activity (responsiveness arm). Patients in the reliability 
arm were eligible for the analyses when they considered themselves in a stable disease state 
while on stable treatment (no change in non-steroidal anti-inflammatory drugs (NSAIDs) over the 
preceding week, with no change in conventional synthetic disease-modifying antirheumatic drug 
(csDMARD) or tumor necrosis factor inhibitor (TNFi) therapy over last 4 weeks). Patients were 
invited to complete the questionnaire at home after an interval of 4-7 days to evaluate reproduci-
bility. Patients in the responsiveness arm required therapeutic change initiated due to high disease 
activity. The therapeutic change could include initiation of NSAIDs, a csDMARD or a TNFi. Pa-
tients were reassessed 12–24 weeks (for NSAIDs 2-24 weeks) after the treatment change had 
been implemented. The patients with longitudinal assessments (reliability and responsiveness) 
were asked to answer a global question at the second assessment and respond as to whether 
their condition was stable, improved or had worsened compared with baseline assessments. Only 
those patients reporting improvement in response to the global change question were analyzed 
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to assess responsiveness. Results of the validation process and the psychometric properties of 
the ASAS HI were presented at various ASAS meetings. Votes were taken from ASAS members 
to confirm the thresholds of ASAS HI. 
Statistics: COSMIN recommendations were followed to test and report measurement properties. 
[21] Psychometric properties were examined according to the OMERACT filter. [22] Descriptive 
statistics were used to characterize the sample. According to the COMSIN checklist, interpretabil-
ity is being summarized as information about percentage of missing items and description of how 
missing items were handled as well as distribution of the (total) ASAS HI score including floor and 
ceiling effects. Distributions of scores were examined for identification of floor and ceiling effects. 
Construct validity was evaluated against other health outcomes (including patient and physician 
global assessment, ASDAS, BASDAI, BASFI, HADS, WPAI, SF-36 summary values (physical 
component summary score (PCS) and mental component summary score (MCS), EQ-5D) in a 
cross-sectional analysis using Spearman correlation. Prior to the analysis, we hypothesized mag-
nitude and direction of correlations, and correlation were considered low if ≤ 0.30, moderate if 
>0.30 and ≤0.50, high if >0.50 and <0.80 and very high if ≥ 0.8. [23] Internal consistency was 
evaluated using Cronbachs α coefficient (adequate: ≥0.70). Test-retest reliability was assessed 
by intraclass correlation coefficient (ICC) (two-way model, single measure) with a 95% CI. An ICC 
of ≥ 0.8 was considered to indicate excellent reliability. Agreement across the scale of the ASAS 
HI was visualized by Bland and Altman plot. Measurement error was assessed by analyzing the 
smallest detectable change (SDC) based on the 95% limits of agreement by using the formula: 
SDC=1.96*standard deviation of the mean difference in ASAS HI of the two assessments in the 
reliability sample/√2. [24] Responsiveness was tested with standardized response mean (SRM) 
after 2-24 weeks depending on the type of medication. SRM was assessed by using the following 
formula: SRM=ASAS HI mean difference/standard deviation of ASAS HI mean difference. A SRM: 
<0.4 was considered to represent a low effect, 0.4 - 0.79 a moderate effect, and ≥ 0.8 a large 
effect. The discriminant ability of the ASAS-HI was assessed by calculating ASAS HI mean scores 
for predefined status groups (ASDAS status groups (inactive, moderate, high and very high), 
BASDAI and BASFI thresholds (<2.0, 2.0-3.99, 4.0-5.99, ≥6.0) by ANOVA. To distinguish between 
relevant health states (an additional relevant aspect of interpretability), two different methods were 
applied: fixed 90% specificity and the closest point to (0,1) [25, 26]. We used the patient global 
assessment at predefined levels (<3 and >6 on NRS and cut-off between good and poor on Likert 
scale) as external constructs for “poor”, “moderate” and “good” health status. We used a global 
rating of change question (Likert scale) as external construct to assess change perceived by the 
patient. A cut off between “improved” versus “no change” or “worse” was used to determine 
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minimal clinically important improvement (MCII). Final choice was based on a consensus during 
ASAS meeting in June 2017 (74 participants, 100% agreement). A p value ≤0.05 were considered 
significant. Statistical analyses were performed using SPSS (Chicago, Illinois, USA) version 23. 
 
Results: 
1.Sample characteristics 
In total, 1593 patients participated in the international validation study (sample size per country 
varied between 15 and 130) (see supplement 3). Of these, 1548 had analyzable data (45 patients 
were excluded because of major incomplete data): 64.9% were male, mean age 42.0 (SD 13.4) 
years, mean symptom duration 14.5 (11.4) (Table 1). There were 1292 (83.5%) patients with 
axSpA, (375 (29.0%) nr-axSpA and 917 (71.0%) AS patients) and 256 (16.5%) patients with pSpA. 
Patients had, on average, moderate disease activity as measured by ASDAS and BASDAI, with 
64.2% treated with NSAIDs and 38.2% were treated with TNFi (Table 1; additional detailed pa-
tients’ characteristics of the whole cohort are presented in supplement 4). As expected, the pa-
tients in the responsiveness sample have a higher level of disease activity at baseline. 
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Table 1: Patient characteristics, values of health status and composite indices at baseline and for reliability and responsiveness assess-
ment 
 
Patient characteristics Baseline(n=1548) Reliability, 1st visit 
(n=578) 
Reliability, 2nd visit 
(n=578) 
Responsiveness 1st 
visit (n=246)§ 
Responsiveness 2nd 
visit§ 
(n=246) 
Age (years) 42.0 (13.4)  45.3 (13.7)  37.2 (12.2) 
Male, n (%) 1005 (64.9)  372 (64.4)  152 (61.8) 
Symptom duration (years) 14.5 (11.4) 16.6 (11.9)  10.9 (9.5) 
Extraspinal manifestation,  
current, n (%) 
arthritis 
dactylitis 
enthesitis 
 
 
301 (19.4) 
50 (3.2) 
261 (16.9) 
 
 
99 (17.1) 
9 (1.6) 
80 (13.8) 
 
 
43 (17.4) 
11 (4.5) 
44 (17.9) 
Extraarticular manifestation,  
current, n (%) 
uveitis 
IBD 
skin psoriasis 
 
 
53 (3.4) 
65 (4.2) 
110 (7.1) 
 
 
17 (2.9) 
32 (5.5) 
51 (8.8) 
  
 
5 (2.0) 
7 (2.8) 
3 (1.2) 
HLA-B27 positive, n (%) 994 (77.0) 350 (73.9) 107 (71.9) 
CRP (mg/l), sample n= 1353 9.8 (16.01) 6.8 (10.2) - 16.7 (22.6) 6.7 (11.4) 
Elevated CRP (≥ 0.5 mg/l), n (%) 765 (49.4) 256 (44.3) - 100 (64.5) 48 (31.0) 
Current NSAID treatment 994 (64.2) 364 (63.0) 119 (76.8) 
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Current csDMARD treatment 402 (26.2) 166 (28.7) 35 (22.6) 
Current TNFi treatment 591 (38.2) 240 (41.5) 23 (14.8) 
ASAS HI (0-17) 6.7 (4.3) 6.2 (4.2) 6.0 (4.2) 8.2 (3.9) 5.7 (4.0) 
ASDAS 2.5 (1.2) 2.6 (1.1) - 3.3 (1.0) 1.9 (1.0) 
BASDAI 4.1 (2.5) 3.7 (2.3) 3.4 (2.1) 5.4 (2.1) 3.0 (2.1) 
BASFI 3.3 (2.8) 3.1 (2.7) 3.1 (2.7) 4.1 (2.7) 2.4 (2.3) 
Pain, NRS 0-10 4.4 (2.9) 3.8 (2.6) 3.6 (2.4) 6.1 (2.4) 3.0 (2.1) 
Physician global, NRS 0-10 3.7 (2.3) 3.1 (2.0) - 5.6 (2.1) 2.4 (1.7) 
Patient global, NRS 0-10 4.5 (2.8) 3.8 (2.5) 3.6 (2.3) 5.9 (2.4) 2.3 (1.7) 
Well being last week 4.4 (2.8) 3.8 (2.6) 3.5 (2.3) 5.8 (2.5) 2.4 (2.0) 
PASS yes 801 (51.7) 368 (63.7) 401 (69.4) 45 (29.0) 130 (83.9) 
HADS anxiety 17.6 (3.9) 18.0 (3.8) 18.3 (3.8) 16.6 (3.9) 18.5 (3.6) 
HADS depression 15.3 (3.5) 15.9 (3.5) 15.7 (3.5) 14.4 (3.4) 16.0 (3.4) 
EQ-5D VAS (0-100 mm) 61.6 (22.7) 63.9 (22.6) 65.3 (22.6) 57.5 (20.2) 67.3 (22.1) 
EQ-5D (pooled)* 0.67 (0.2) 0.7 (0.2) 0.7 (0.2) 0.7 (0.2) 0.7 (0.2) 
SF-36 PSC 38.9 (10.5) 40. 4 (10.2) 40.6 (10.2) 34.4 (9.3) 41.3 (9.5) 
SF-36 MSC 47.0 (11.5) 48.6 (11.2) 48.5 (11.2) 43.5 (10.9) 48.7 (11.0) 
WPAI, presenteeism 29.2 (26.0) 23.4 (23.4) 21.9 (21.1) 39.3 (27.4) 23.6 (21.9) 
WPAI, absenteeism& 16.0 (32.3) 11.68 ± 27.5 10.5 (27.3) 31.0 ± 42.7 10.9 ± 27.3 
Values are presented as mean(SD) or absolute number (%). Percentages are % of available data 
Fewer than 5% of the data were missing, except for HLA-B27 with 16.6%, CRP with 8.7% and EQ-5D with 9.7% at baseline visit and ASDAS (in responsiveness  arm) with 7.3%. 
CRP and physician global were not measured in the reliability arm at the second visit 
*The phrase EQ pooled means that EQ-5D-5L analysis was based on the 5-level value set for UK except for France, Germany, Netherlands, Spain, Thailand and USA for which the country-
specific value set was used. 
§ Only data analyzed from those patients who stated that they improved during the time interval 
&calculated for employed patients (n=961), see supplement 4 
11 
 
ASAS HI= ASAS Health Index; ASDAS=Ankylosing Spondylitis Disease Activity Index; BASDAI= Bath Ankylosing Spondylitis Disease Activity Index; BASFI=Bath Ankylosing Spondylitis 
Functional Index; CRP=C-reactive protein; csDMARD=conventional synthetic Disease modifying antirheumatic drug; EQ-5D=Euro Quality of Life 5 Dimension; HLA=Human leukocyte anti-
gen; HADS=Hospital Anxiety Depression Scale; IBD=Inflammatory Bowel Disease; MSC=Mental component summary score; NSAIDs=Non-steroidal antirheumatic drug; NRS=numerical 
rating scale; PASS=Patient Acceptable Symptom State; PSC=Physical component summary score; NA= not applicable; SF-36=Short-form 36; TNFi=Tumuor necrosis factor inhibitor; 
VAS=Visual analogue scale; WPAI=Work Productivity and Impairment Scale. 
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2. Psychometric properties of the ASAS HI 
2.1. Interpretability:  
The mean total score in the population sampled for the ASAS HI was 6.7 (SD 4.3). A total score 
was calculated for respondents in which not more than 20% of the data were missing (see also 
Users manual published in supplement 1). Numbers of missing values were limited and occurred 
between 0.1 and 0.3% (supplement 5). Floor (percentage of the respondents who had the lowest 
possible (total) score) or ceiling effects (percentage of the respondents who had the highest pos-
sible (total) score) of the ASAS HI in this analysis were acceptable (6.9% and 0.8%), respectively) 
(Figure 1). 
 
2.2. Construct validity: Construct validity showed Spearman correlation coefficient ranging from 
moderate (WPAI absenteeism: 0.38) to high (BASFI: 0.71 or SF-36 PSC 0.73). 
 
As hypothesized, the ASAS HI had high correlation with patient global (r=0.57), pain (r=0.60), 
spinal pain (r=0.54), SF-36 MCS (r=0.59), HAD-S (r - 0.55 and -0.57) BASFI, ASDAS (r=0.61), 
presenteeism (r=0.60), BASDAI, BASFI, EQ-5D and SF-36 PCS (r>0.70). The correlation of 
ASAS HI with physician global (r=0.49), and absenteeism (r=0.38) was moderate (Table 2). Of 
note, correlation of ASAS HI with age was weak (r=0.10). Hypothesis about magnitude and di-
rection of correlation was confirmed in 68.7 % of variables. 
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Table 2: Spearman correlation between ASAS HI scores and other PRO 
 
 Hypothesis Spearman correlation Confirmation* 
Pain High 0.60 Yes 
Spinal pain High 0.54 Yes 
Patient global High 0.57 Yes 
Physician global Moderate 0.49 Yes 
ASDAS High 0.61 Yes 
BASDAI High 0.70 Yes 
BASFI High 0.71 Yes 
HADS anxiety Moderate -0.55 No 
HADS depression Moderate -0.57 No 
EQ-5D VAS (0-100 mm) High 0.45 No 
EQ-5D High -0.72 Yes 
SF-36 PSC High -0.73 Yes 
SF-36 MSC Moderate -0.59 No 
WPAI presenteeism Moderate 0.60 No 
WPAI absenteeism Moderate 0.38 Yes 
Well being last week High 0.61 Yes 
ASDAS=Ankylosing Spondylitis Disease Activity Index; BASDAI= Bath Ankylosing Spondylitis Disease Activity Index; BASFI=Bath 
Ankylosing Spondylitis Functional Index; EQ-5D=Euro Quality of Life 5 Dimension; HADS=Hospital Anxiety Depression Scale; 
MSC=Mental sum component; PSC=Physical sum component; SF-36=Short-form 36; WPAI=Work Productivity and Impairment Scale. 
*Column indicates whether hypothesis generated prior to analysis about magnitude and direction of correlation was confirmed in the 
specific variable. 
 
2.3. Internal consistency: ASAS HI scores showed a high Cronbachs-α of 0.93. Internal con-
sistency of ASAS-HI did not vary much across different disease groups (0.93 for AS, 0.94 
for nr-axSpA, and 0.91 for pSpA). 
 
2.4. Reliability and measurement error: A total of 770 patients had a second assessment for 
reliability. Of these, 192 patients had to be excluded because of missing data (n=54), patients not 
being stable (n=74) or second assessment performed outside timeframe (n=64). Finally, 578 
(75.1%) patients who considered themselves to be in a stable state were analyzed (Table 1). The 
mean (SD) baseline ASAS HI was 6.2 (4.2) and the second ASAS-HI was 6.0 (4.2). Reliability 
was excellent with an ICC of 0.87 (95%CI 0.84 to 0.89) and ICCs were comparably high in all 
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disease subtypes (AS 0.87 (95%CI 0.84 to 0.89); nr-axSpA 0.89 (95%CI 0.85 to 0.93); pSpA 0.83 
(95%CI 0.75 to 0.88)). Bland-Altman plot shows a good agreement between ASAS HI sumscore 
at first and second assessment. No systematic differences in sumscore for the two measurement 
timepoints were found. Calculation of the limits of agreement (and the SDC) was based on the assumption 
that reliability was homoscedastic over the entire range of ASAS HI although this was not completely the 
case as the variation was somewhat more pronounced in the middle of the range.  (Figure 2). The SDC 
was calculated as 3.0, which corresponds to the minimum change beyond measurement error that 
can be detected in an individual patient over time. 
 
2.5. Responsiveness: 353 patients were allocated to the sensitivity to change arm because of 
initiation of a new treatment. 107 patients had to be excluded from the 353 initial patients because 
of missing data (n=47), patients deteriorating during time interval (n=12), patients not reporting a 
change in their disease state (n=47), and second assessment performed outside of timeframe 
(n=1). Finally, 246 (69.7%) estimated themselves to have improved between visits and were an-
alyzed. 78 patients started NSAIDs, 41 patients a csDMARD, and 127 patients TNFi. The SRM 
was -0.44 for NSAIDs (moderate), -0.69 for csDMARDs (moderate) and -0.85 for TNFi (large).  
 
2.6. Discriminant ability: The ASAS HI discriminated well between patients with different disease 
activity states (measured by ASDAS and BASDAI) and function (measured by BASFI) (Table 3). 
The groups with greater disease activity and more impaired functioning had higher mean ASAS 
HI scores (indicating impaired health) than those with lower disease activity. 
 
Table 3: Discriminant ability of the ASAS HI with respect to disease activity and physical 
functioning 
Disease activity     F test p-value 
ASDAS 
thresholds 
Inactive 
(n=245) 
Moderate 
(n=283) 
High 
(n=500) 
Very high 
(n=289) 
  
ASAS HI 2.9 (3.1) 5.1 (3.5) 7.3 (3.6) 10.4 (3.5) 230. p<0.001 
BASDAI 
thresholds 
< 2.0 
(n=372) 
2.0-3.9 
(n=405) 
4.0-5.9 
(n=347) 
≥ 6.0 
(n=414) 
  
ASAS HI 2.8 (2.9) 5.2 (3.1) 7.8 (3.3) 10.5 (3.4) 421.4 p<0.001 
Functioning     F test p-value 
BASFI 
thresholds 
< 2.0  
(n=633) 
2.0-3.9 
(n=322) 
4.0-5.9 
(n=258) 
≥ 6.0 
(n=323) 
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ASAS HI 3.7 (3.1) 6.5 (3.1) 8.6 (3.4) 11.2 (3.1.6) 438.0 p<0.001 
* All values given as mean (SD) 
 
2.7. Cut-off values for interpreting health status based on ASAS HI scores: Final cut-offs for ASAS 
HI scores to distinguish poor versus moderate, and moderate versus good health are presented 
in Table 4. All analyzed scenarios with application of different external anchors and different meth-
odological approaches are presented in Supplement 6. In order to balance sensitivity and speci-
ficity a threshold of ASAS HI which differentiated patients with “good/very good” health from those 
with “moderate” health state, was identified as being 5.0. In contrast, the 90% specificity criterion 
was considered to be the most clinically relevant threshold of ASAS HI for “moderate” versus 
“poor/very poor” health identified as a score of 12.0 or above. 
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Table 4: Analysis of cut-off values for ASAS HI scores to define health status 
 
ASAS HI cut offs and external criterion n (P+N) 90%SP (SE/SP) (0,1) (SE/SP) AUC 
Cut off between "good" and "moderate" functioning         
Patient global, Likert very good/good versus all others 1531 (624+907) 3.0 (49.5/90.0) 5.7 (73.5/75.9) 0.81 
Patient global, NRS <3 1533 (435+1098) 2.3 (46.2/90.5) 5.0 (76.5/71.9) 0.80 
ASAS HI cut offs and external criterion n (P+N) 90%SP (SE/SP) (0,1) (SE/SP) AUC 
Cut off between "moderate" and "poor" functioning         
Patient global, Likert very poor/poor versus all others 1531 (304+1227) 12.0 (39.5/90.5) 7.4 (79.3/67.6) 0.80 
Patient global, NRS >6 1533 (425+1108) 11.7 (34.3/89.6) 7.4 (71.3/69.7) 0,76 
 
P+N, number of positive + negative results according to the external criterion, 90%SP, cut-off according to the 90% specificity criterion, SE, sensitivity, SP, specificity, (0,1), cut-off according 
to the closest point to (0,1) criterion, AUC, area under the curve.,  
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Attempts to define a clinically important improvement proved an elusive target since scores were 
too heterogeneous. We therefore recommend using the SDC value of 3.0 to determine change in 
ASAS HI in individual patients and present the % of patients with a change of ≥3.0. 
Applying these thresholds within the validation cohort, we were able to show that the three defined 
health status groups within ASAS HI could discriminate with respect to both disease activity, func-
tioning and health measures (Table 5). The two cut-off values delineating the three health statuses 
were agreed upon after discussion and voting by 74 ASAS members during their EULAR meeting 
2017 (74 approval, 0 decline, 0 abstention). 
 
Table 5: Discriminant ability of the health status groups 
Health state (number, 
%patients) 
Good ≤5.0 
(n=553, 36 %) 
Moderate <5.0 - 
<12.0 
(n=755, 49%) 
Poor ≥ 12.0 
(n=235, 15%) 
ASAS HI 2.1 (1.5) 7.8 (2.0) 13.7 (1.5) 
BASFI 1.2 (1.5) 3.8 (2.5) 6.3 (2.3) 
BASDAI 2.1 (1.6) 4.8 (2.1) 6.6 (1.9) 
ASDAS 1.7 (0.9) 2.6 (2.1) 3.7 (1.1) 
SF36 PSC 47.6 (7.1) 35.7 (8.8) 28.7 (6.6) 
EQ-5D 0.8 (0.1) 0.6 (0.2) 0.4 (0.2) 
* Values given as mean (SD) otherwise indicated 
 
Discussion 
The manuscript presents the psychometric properties of the original English ASAS HI and its dif-
ferent translations, as obtained in a large international cohort. We show that the ASAS HI is a 
valid, reliable and responsive measure of functioning and health in patients with SpA on a global 
level. Interpretability was good as has been shown for different aspects. In this paper, we report 
the values for the entire cohort and country-specific results will be published separately in the 
language of the specific country. Generally, the results were similar in the various coun-
tries (data not shown). 
Since the ASAS HI contains only 17 items with a dichotomous response option addressing all 
important aspects of patient complaints, administration of the questionnaire is feasible as it has 
been shown in a previous field test.[10] The calculation to obtain a single sum score is simple and 
quick to undertake. Floor effect was acceptable with almost no ceiling effect observed in our study. 
The scores have good face validity and the ASAS HI exhibited excellent correlation with other 
measures covering a range of health outcomes. Analysis of construct validity demonstrated a 
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strong association between ASAS HI sum score and both disease activity and functional disability, 
indicating that the ASAS HI is measuring a broader concept than just disease activity or physical 
functioning. In addition, the high correlation between ASAS HI and patient global assessment as 
well as generic health measures (such as SF-36) suggest that patients do not make substantial 
distinctions between disease-specific and more generally worded questionnaires. We noted in our 
cohort a weaker correlation between ASAS HI and physician global as well as discordance be-
tween physician and patient global scores at baseline. However, the discordance between patient 
responses and physician response is very small and not comparable to those reported in literature. 
[27, 28] 
We were able to show that the ASAS HI is applicable in all patients with SpA irrespective of the 
disease subgroup. Similar results in internal consistency between AS, nr-axSpA and pSpA provide 
support for the use of these questionnaires in the whole group of SpA. This is an important finding 
as the ASAS HI was originally developed in patients with AS. However, use of the ASAS HI in 
pSpA patients should be carefully checked and its applicability should be further investigated to 
gain more insights into this subgroup of patients. 
There is a debate about which measure is suitable for assessing responsiveness. Our 
choice is SRM, which is not recommended according to the COSMIN guidelines.[21] How-
ever, SRM is one of the widely used responsiveness measures and there is also critique published 
in the literature about this part of the COSMIN guidelines. [29] One of the arguments is that the 
SRM is more reflecting the magnitude of the event than providing information on the measure. 
Indeed, we do show that the SRM is better for start of bDMARDs than for NSAIDs. However, 
providing the SRM is a useful information for researchers who want to use the ASAS HI as an 
outcome measure in a trial. 
This study has clear strengths and weaknesses. Strengths include the involvement of 23 countries 
with 18 country-specific translations with different cultures and socioeconomic backgrounds within 
the validation process. [10]Thus, the domains of functioning and health assessed in the question-
naire are likely to be relevant across countries and cultures. However, qualitative research about 
this issue is lacking. One relative weakness of this international validation study may be consid-
ered the small sample size in some countries, especially in the longitudinal arm. However, the 
results of the study do show that the psychometric properties are robust and meaningful. The 
ASAS HI can be used in clinical trials to evaluate the impact of SpA and its treatment on overall 
functioning and health in patients with SpA and also to compare disease impact in cohorts and 
populations. Further research is needed to address the question whether and how the ASAS HI 
is applicable in daily routine care to guide treatment decisions. 
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In conclusion, the ASAS HI proved to be a valid, interpretable, reliable, and responsive question-
naire to assess overall functioning and health in this global international validation study including 
19 languages. 
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Figure 1: Score distribution (0-17) of the ASAS HI at baseline 
 
Figure 2: Bland and Altman Plot. The differences between total sum score of ASAS HI at two time 
points were plotted against the mean of the two values together with the SDC   
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